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Abstract
Apical Membrane Antigen 1 (AMA1), a merozoite protein essential for red cell invasion, is a candidate malaria vaccine
component. Immune responses to AMA1 can protect in experimental animal models and antibodies isolated from AMA1-
vaccinated or malaria-exposed humans can inhibit parasite multiplication in vitro. The parasite is haploid in the vertebrate
host and the genome contains a single copy of AMA1, yet on a population basis a number of AMA1 molecular surface
residues are polymorphic, a property thought to be primarily as a result of selective immune pressure. After immunisation
with AMA1, antibodies more effectively inhibit strains carrying homologous AMA1 genes, suggesting that polymorphism
may compromise vaccine efficacy. Here, we analyse induction of broad strain inhibitory antibodies with a multi-allele
Plasmodium falciparum AMA1 (PfAMA1) vaccine, and determine the relative importance of cross-reactive and strain-specific
IgG fractions by competition ELISA and in vitro parasite growth inhibition assays. Immunisation of rabbits with a PfAMA1
allele mixture yielded an increased proportion of antibodies to epitopes common to all vaccine alleles, compared to single
allele immunisation. Competition ELISA with the anti-PfAMA1 antibody fraction that is cross-reactive between FVO and 3D7
AMA1 alleles showed that over 80% of these common antibodies were shared with other PfAMA1 alleles. Furthermore,
growth inhibition assays revealed that for any PfAMA1 allele (FVO or 3D7), the cross-reactive fraction alone, on basis of
weight, had the same functional capacity on homologous parasites as the total affinity-purified IgGs (cross-reactive+strain-
specific). By contrast, the strain-specific IgG fraction of either PfAMA1 allele showed slightly less inhibition of red cell
invasion by homologous strains. Thus multi-allele immunisation relatively increases the levels of antibodies to common
allele epitopes. This explains the broadened cross inhibition of diverse malaria parasites, and suggests multi-allele
approaches warrant further clinical investigation.
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Introduction
Malaria continues to be one of the most important human
parasitic diseases, with a global estimate of about 247 million
clinical cases and almost 1 million deaths annually [1]. The greater
burden of the disease is caused by Plasmodium falciparum in sub-
Saharan Africa, where children under 5 years old, pregnant
women (mostly primigravid) and their foetuses are at the greatest
risk. A cost-effective vaccine would form a powerful additional
component in control strategies for malaria and a number of
Plasmodium antigens expressed at different stages of the parasite’s
complex life cycle are currently undergoing clinical evaluation [2].
Among the candidates in clinical testing is Plasmodium falciparum
Apical Membrane Antigen 1 (PfAMA1), a protein expressed in
sporozoites and in merozoites of both liver and asexual
erythrocytic development stages, the vaccine-related properties
of which has recently been reviewed [3]. In brief, AMA1 is a
merozoite membrane protein initially located in micronemes.
Around the time of merozoite release from schizonts AMA1 is
translocated to the merozoite surface, where it is involved in
merozoite/red cell interactions preceding invasion [4–6]. Anti-
AMA1 antibodies can interfere with AMA1 function and prevent
invasion in vitro [7–10], this effect requiring immunisation with
correctly folded AMA1 [11,12]. The ectodomain of AMA1, which
is the vaccine target, is shed as 44 and 48 kDa alternate proteins
from the merozoite surface upon RBC invasion [13]. The amino
acid sequence of the ectodomain has 16 cysteine residues that are
conserved in all AMA1 sequences and these form disulphide bonds
that result in a structure with three distinguishable but interactive
domains (reviewed in [3]).
Polymorphism in AMA1 has long been evident [14], thought to
be an effect of selection exerted by host immune responses [15,16].
Immunisation with one allele of AMA1 ectodomain induces
antibodies that inhibit homologous parasite growth in vitro to a
greater extent as compared to heterologous parasites [12,17,18].
The induction of functional antibodies has been demonstrated in a
number of ways, including rodent and primate challenge/passive
immunisation studies [15,19–21]. In some cases, and particularly
with the rodent parasite P. chabaudi, antibodies are protective
against parasites expressing homologous AMA1 but not those
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conserved and strain-specific PfAMA1 antibody epitopes have
been observed in malaria-exposed humans [23,24].
About 10% of amino acid residues of AMA1 are polymorphic,
and even when appearing distant in the primary structure, may
cluster within the tertiary structure [25–27]. These polymorphic
clusters occur predominantly on one surface of the AMA1
molecule, which suggests that this face is accessible to antibody
at the parasite surface [28]. This points to the significance of
strain-specific epitopes in eliciting protective antibodies [12,17,29],
although conserved AMA1 epitopes are also targets for inhibitory
antibodies [30,31].
Antibodies induced by immunisation with a combination of two
allelic forms of PfAMA1 (FVO and 3D7) inhibit the in vitro growth
of both parasite strains to the same extent as antibodies raised
against the single respective antigens [17], although there was no
significant gain in growth inhibition against unrelated parasite
strains. Similar observations from antigen recognition in ELISA
have been reported in human trials with vaccine candidates
incorporating PfAMA1 proteins from the FVO and 3D7 parasite
strains [32–34], and multi-allele immunisation has been proposed
as one way of overcoming strain-specificity in PfAMA1 responses.
The question remains whether antibodies elicited by a multi-allele
vaccine would be effective against parasites expressing a relatively
distant natural PfAMA1 allele from those of the vaccine
components.
An effective PfAMA1 vaccine will be required to overcome
allelic diversity. We have therefore obtained sera from rabbits
immunised separately with the full ectodomain PfAMA1 from
FVO, 3D7 and HB3 strains, as well as sera from rabbits
immunised with a mixture of these 3 PfAMA1 alleles, to assess
the feasibility and mechanism of broadening the antibody response
by immunisation with a mixture of PfAMA1 alleles. Strain-specific
and cross-reactive anti-PfAMA1 antibody fractions were also used
to assess the relative importance and contribution of these two IgG
fractions to the overall in vitro functional capacity of anti-PfAMA1
antibodies. The study was also used to validate the competition
ELISA methodology for assessing antibody responses to naturally-
occurring PfAMA1 antigens and establish it as an analytical tool
for dissecting humoral immune responses to polymorphic antigens.
Our data shows the feasibility of broadening the functional
antibody response to PfAMA1 by immunisation with a mixture of
three PfAMA1 alleles. Such a vaccine preferentially induces the
expression of antibodies to epitopes that are common to the
vaccine component alleles by diluting out responses to the strain-
specific epitopes. Common or cross-reactive antibodies, in the
absence of strain-specific antibodies, are capable of inhibiting the
in vitro growth of parasites represented by the vaccine PfAMA1
alleles as well as parasites expressing PfAMA1 alleles not included
in the vaccine. The data indicates that PfAMA1 multi-allele
vaccine strategies should be pursued and provide a justification for
further clinical investigation.
Methods
Protein Production and Rabbit Immunisations
The full ectodomain of AMA1 allelic forms from the P.
falciparum strains FVO, HB3, 3D7 and CAMP were expressed in
Pichia pastoris by a similar methodology as described elsewhere
[35,36]. Potential N-glycosylation sites were removed from the
PfAMA1 gene sequences by mutagenesis before expression.
All animals were handled in strict accordance with good animal
practice as defined by the Belgian national animal welfare
regulations, and all animal work was approved by the ethics
committee of the Centre d’Economie Rurale (CER Groupe,
Marloie, Belgium). Rabbit immunisations were done intramuscu-
larly (Eurogentec SA, Seraing, Belgium) with 4 doses of PfAMA1
formulated in Montanide ISA720 (Seppic, Paris, France) as
adjuvant, according to the manufacturer’s instructions. New
Zealand white rabbits were immunised on days 0, 28, 56 and
82, and the final bleed sera collected on day 95 were used in this
study. Four groups of 2 rabbits each were immunised as follows:
the first 3 groups received 30 mg/dose of FVO AMA1, 3D7
AMA1 or HB3 AMA1 respectively. The 4
th group received
30 mg/dose of a mixture (10 ug each) of the 3 PfAMA1 alleles, also
formulated in the same adjuvant.
Antibody Purification
Serum antibodies were purified on Protein A sepharose (GE
Healthcare, Etten-Leur, The Netherlands) columns. Binding and
elution buffers (Pierce, Rockford, IL) were used according to
manufacturer’s protocols. After elution, antibodies were concen-
trated and exchanged into RPMI 1640 using AmicronUltra-15
tubes (30-kDa cutoff; Millipore, Ireland). Antibodies were
subsequently sterile-filtered with 0.22 mm Ultrafree MC centrifu-
gal filter units (Millipore), the concentration determined with a
Nanodrop ND1000 spectrophotometer (Nanodrop Technologies,
Wilmington, DE) and stored at 220uC until use.
3D7-specific AMA1 antibodies were purified from the total
serum IgGs (protein A purified) of a 3D7-immunised rabbit using a
3D7 AMA1-coupled sepharose matrix. The eluted 3D7-specific
IgG fraction was further separated into strain-specific (flow-
through) and cross-reactive (eluate) IgGs by passage over an FVO
AMA-coupled sepharose matrix. Protein A purified anti-FVO
AMA1 antibodies were also affinity fractionated as has been
described for anti-3D7 AMA1, first over an FVO AMA1-coupled
sepharose matrix, then the eluate over a 3D7 AMA1-coupled
matrix (Figure S1). The constituent IgG in all fractions were
confirmed by ELISA and all fractions were concentrated, sterile
filtered and stored at 220uC until use.
ELISA
Competition ELISA assays were carried out with AMA1 from 4
different P. falciparum strains (FVO, HB3, 3D7 and CAMP) to
define specificities of antibodies raised against the 3 PfAMA1
vaccine antigens (FVO, 3D7, HB3). An initial titration was
performed to determine the optimal dilution of purified IgG
required for the competition assay with each of the 3 vaccine
antigens as coating antigen. Briefly, 96-well flat bottom Microlon
titre plates (Greiner, Alphen a/d Rijn, The Netherlands) were
coated with 100 ml/well of 1 mg/ml FVO, 3D7 or HB3 AMA1
ectodomain at 4uC overnight. Plates were washed 5 times with
PBS, 0.05% Tween 20 (PBS-T) using an automated plate washer
(Bio-TEK Instruments, Inc, VT) and blocked with 200 ml/well of
3% BSA in PBS-T for at least 1.5 h. IgG samples were titrated 3-
fold from 1:10,000 and incubated for 2 h. A pool of sera from
rabbits immunised with a mixture of the 3 PfAMA1 alleles, titrated
2-fold from 1:100,000, was used as standard calibrator on all
plates. Protein A purified IgG from rabbit pre-immunisation sera,
titrated 2-fold from 1:10,000, was used as negative control on all
plates. All samples, standards and controls were diluted with 0.5%
BSA in PBS-T and added in duplicate (100 ml/well). After sample
incubation, plates were washed and 100 ml/well of 1:1250-diluted
goat anti-rabbit IgG/alkaline phosphatase conjugate (Pierce,
Rockford, IL) added for 1 h. Plates were then washed, incubated
with 100 ml/well p-nitrophenyl phosphate (pNPP; Fluka, Poole,
UK) as substrate for 30 min. and the optical density (OD) at
405 nm read with a 96-well ELISA plate reader (BioRad, Japan).
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curve included on each plate using an excel-based four-parameter
logistic function, which after correcting for variation approximates
the IgG dilution that gives an OD of 1.0 to one arbitrary unit
(1 AU).
Dilutions that resulted in an AU of 2 were extrapolated for each
rabbit serum/purified IgG and used for the subsequent antigen
competition assay. The assay involved co-incubation of different
allelic forms of PfAMA1 with the same dilution of test IgGs in
plates coated entirely with one of the vaccine PfAMA1 alleles, such
that there was competition between the added (competitor)
antigens and the coated antigen for binding to test IgGs. The
procedure was similar to that described for the pre-titration,
except for the addition of 50 ml/well rabbit IgG at 2 times the
desired dilution (equivalent to an AU of 4) to 50 ml/well of titrated
soluble antigens in coated and blocked plates. Antibodies from all
rabbits were co-incubated with the 4 PfAMA1 alleles (FVO, HB3,
3D7, CAMP) separately, on plates coated with either FVO, HB3
or 3D7 AMA1. The competitor/soluble antigens were titrated 3-
fold from 30–0.005 mg/ml over 9 duplicate wells, and the 10th
sample wells were left without soluble antigen. The appropriately
diluted IgG sample was then added to all 10 duplicate wells for
each soluble antigen and after incubation for 2 h, plates were
developed as described above.
To further dissect the nature and underlying mechanism of
humoral responses to the different PfAMA1 alleles, IgG pools
made from the single allele immunisations, were also compared
with IgGs from the single and multi-allele immunisations by
competition ELISA.
Duplicate OD values (from residual antibody binding to the
coated antigen after competition) for wells that had soluble
antigens were converted to arbitrary units and expressed as a
percentage of AU values from wells without soluble antigen. The
percent residual binding values were then plotted (points)
alongside the predicted percent values (curves) based on a least
squares approximation from the following four-parameter logistic
function;
Y~
100{Y min ðÞ
1ze Xmid{X ðÞ sc zY min
where Y is the predicted % residual binding, Ymin is the maximal
depletion at infinite soluble antigen concentration (minimum
value), X is the soluble antigen concentration (log scale), Xmid is
the soluble antigen concentration (log scale) at which 50%
antibody depletion is achieved (midpoint between the maximum
and minimum depletion values), and sc is the slope of the curve.
Percent antibody depletion for any competitor/soluble antigen is
therefore the difference between 100% (binding in the absence of
soluble antigen) and the residual binding.
The competition assay was initially validated by testing anti-
FVO AMA1 IgG or serum at dilutions equivalent to 0.2, 0.5, 1, 2,
4 and 8 times the titre (1 AU) on FVO-coated plates (100 ng/well)
with the same soluble antigen concentrations (3-fold titration from
30 mg/ml over 9 duplicate wells). The assay was shown to be
reproducible and independent of the antibody source (serum or
purified IgG) and the dilution provided the OD values in wells
with no competitor antigen were within the linear portion (ODs of
0.3–2.5 over blank) of the standard curve.
Antibody Avidity Measurements
The binding capacity of antibodies raised by single and mixed
allele immunisations were determined by avidity ELISA with
sodium isothiocyanate (NaSCN) elution. Briefly, 96-well flat
bottom Microlon titre plates were coated with AMA1 allelic
antigens as described above, and after blocking, incubated with a
pre-determined titre (1 AU) of sera from immunised rabbits for
1 h. Plates were then washed and incubated with an increasing
concentration of NaSCN (0, 0.25, 0.5, 1.0, 1.25, 1.5, 1.75, 2.0,
2.25, 2.5 and 3.0 M) in different duplcate wells for 15 min. Plates
were again washed and subsequently developed with goat anti-
rabbit IgG/alkaline phophatase conjugate and pNPP substrate as
already described. Avidity index, the concentration of NaSCN
required for 50% dissociation of bound antibodies (relative to
duplicate wells without NaSCN) was the extrapolated in Microsoft
excel for each rabbit serum sample.
Parasite Cultures and Growth Inhibition Assays
Protein A and affinity-purified IgG fractions were tested for in
vitro activity in parasite growth inhibition assays (GIAs) as
described elsewhere [18]. All IgGs and IgG pools were tested in
triplicate on FCR3, NF54, HB3 or CAMP parasite strains at a 3-
fold serial dilution from 6 mg/ml (protein A purified IgG) or
1 mg/ml (affinity-purified IgG) in 96-well culture plates. Parasites
were cultured under standard conditions (an atmosphere of 5%
CO2,5 %O 2, and 90% N2,3 7 uC), and the PfAMA1 antigen
expressed by all parasite strains were verified by PCR and
restriction fragment length analysis. Parasite cultures were
mycoplasma-free and synchronized with 0.3 M alanine, 10 mM
Hepes pH 7.5 before use in an assay. Late trophozoite/early
schizont stages at a parasitaemia of 0.360.1% and 2% final
haematocrit were used in all assays. The final culture volume was
50 ml/well and parasites were incubated for 40–45 hrs. Parasite
growth was assessed by measuring parasite lactate dehydrogenase
levels with the lactate/diaphorase/APAD substrate system, and
plates were read at 655 nm after 30 min of development. Parasite
growth inhibition was expressed as;
% inhibition~100{
A655Sample{A655RBC ðÞ
A655SZ{A655RBC ðÞ
|100
where A655Sample is the OD655 for any test sample well, A655SZ is
the average OD655 of schizont control wells included on each plate
and A655RBC is the average OD655 of RBC control wells. The data
was presented as the arithmetic mean % inhibition from each
sample triplicate.
Statistical Analyses
Residual binding (or minimum) values in competition ELISA,
and the corresponding confidence intervals were generated by a 4-
parameter logistic fit with least squares approximation using the R
statistical package (R Development Core Team, 2008, version
2.8.1). Comparisons between minimum values estimated in the
non-linear regression were done with Student’s t test; p
values,0.05 were considered statistically significant. All plots
were prepared with the R statistical package. Since antibody
depletion patterns in ELISA were similar for IgG samples from the
two rabbits in each immunisation group, data presented (ELISA
and GIA) are for only one rabbit per group and is therefore of a
qualitative nature.
Results
Competition ELISA Validation
The competition ELISA assay used was based on coating plates
with one allele of PfAMA1 and mixing test antibody samples with
the same or other PfAMA1 alleles to determine the degree to
which antibody binding to the coating material was inhibited. The
AMA1 Multiallele Immunisation
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initial serum/IgG concentrations (CV was generally below 2%,
and maximally 15% for very low OD values). Antibody depletion
patterns were similar irrespective of whether serum or protein A-
purified IgG samples were used for the assay (data not shown).
Depletion patterns, plotted as percentages, were similar irrespec-
tive of the final serum/IgG dilution used provided the OD value
was within the linear portion of the standard curve. An 8-fold
active dilution range (0.5–4 AU) gave optimal results (Figure S2).
Dilutions above this range (8 AU or higher) shifted the curves to
the left (suggesting less antigen required for depletion compared to
dilutions within the linear range), and dilutions below the range
(0.2 AU or lower) shifted curves to the right (suggesting more
antigen required for depletion compared to dilutions within the
linear range) (Figure S2). Antibody depletion patterns were also
very similar for each pair of rabbits immunised with the same
antigen, irrespective of the original antibody response/titre (data
not shown).
A 4-parameter logistic plot was used to assess the reproducibility
and robustness of the assay by comparing data from three different
assays and at three different antibody dilutions using final ODs
within the linear portion. A statistical comparison of the minimum
values, the most informative parameter for comparing antibody
specificities by this assay, is presented in Table 1 for an assay
involving co-incubation of 4 different competitor antigens with
total IgG from an FVO AMA1 immunisation in FVO AMA1-
coated plates. For any competitor antigen, the minimum value
represents the proportion of antibodies that do not bind to the
competitor antigen, but do bind to the coating antigen. This
fraction of the test antibodies represents the strain-specific
component with respect to the competitor antigen, while the
fraction depleted by the competitor antigen represents antibodies
that are capable of binding to both the coated and competitor
antigens. With the exception of HB3 AMA1, competitor antigens
had highly consistent minimum values between assays and with
different starting antibody dilutions. Minimum values for 3D7 and
CAMP AMA1 competitor antigens were consistently and
significantly different from the homologous FVO AMA1 compet-
itor antigen. The shape of the HB3 AMA1 competitor antigen
curve suggested that at higher concentrations, further antibody
depletion was possible. This was not the case for the other
competitor antigens as the minimum values had almost reached a
plateau at the highest antigen concentration used. As a result,
relatively wide confidence intervals were obtained for minimum
values when HB3 AMA1 competed for anti-FVO AMA1
antibodies (Table 1).
The slope describes an inverse relationship between antibodies
not depleted by the competitor antigen and the log-concentration
of competitor antigen, with a higher absolute value representing a
steeper curve. At different antibody dilutions for FVO, 3D7 and
CAMP AMA1 competitor antigens, the slope was fairly consistent
between assays (20.26 to 20.52), with most values around 20.40.
Xmid, like IC50, is the concentration of competitor antigen that
results in 50% antibody depletion. However, interpretation of this
parameter is confounded by the different minimum values for the
different competitor antigens (Figure S2).
Antibodies from Multi-Allele Immunisation Have an
Increased Cross-Reactivity
Once validated, the competition ELISA assay was used to
compare the relative proportions of cross-reactive and strain-
specific antibody fractions induced by single and mixed PfAMA1
allele immunisations. Antibody depletion patterns revealed
significantly increased cross recognition of all heterologous
competitor antigens by antibodies from the mixed allele
immunisation (anti-Combi) compared to those from the single
allele immunisations (Figure 1, Table 2). This implies that there is
a higher proportion of antibodies to common epitopes in the
mixed allele immunisation compared to the proportion in any
single allele immunisation. For example, recognition and depletion
of antibodies by the FVO AMA1 competitor antigen increased
significantly from 60% (40.2% residual binding) for IgGs from the
3D7 AMA1 single allele immunisation to over 80% (17.8%
residual binding) for anti-Combi antibodies (p,0.0001) in
competition assays with 3D7 AMA1 as coating antigen
(Figure 1A). Similarly, depletion by HB3 AMA1 in the same
assays was almost 70% (29.9% residual binding) with anti-3D7
AMA1 antibodies and up to 95% (5.73% residual binding) with
anti-Combi antibodies (p=0.0006). Depletion by CAMP AMA1,
which was not a component antigen of the mixed allele vaccine,
also increased significantly from 60% (39.9% residual binding)
with anti-3D7 AMA1 antibodies to almost 75% (25.7% residual
binding) with anti-Combi antibodies (p=0.0008). Similar trends of
increasing recognition and depletion were observed by comparing
antibodies from single allele immunisation with HB3 AMA1 and
FVO AMA1 with the mixed allele immunisation when assays were
performed with the respective PfAMA1 alleles as coating antigens
(Figures 1B and 1C). Depletion of anti-Combi antibodies was
consistently highest for all competitor antigens when FVO AMA1
was used as the coating antigen. CAMP AMA1 highly recognized
and depleted anti-FVO AMA1 antibodies (31.6% residual
binding) and least recognized anti-HB3 antibodies (55.0% residual
Table 1. Residual IgG binding estimates from competition ELISA validation.
Competitor antigen (PfAMA1)
FVO HB3 3D7 CAMP
Expt.1 (1 AU) 4.2 (21.8–10.2) 14.2 (23.8–32.2) 50.1 (43.7–56.5) 33.1 (29.3–36.8)
Expt.1 (2 AU) 3.3 (21.9–8.5) 8.4 (218.3–35.0) 50.2 (45.0–55.3) 34.1 (29.6–38.5)
Expt.2 (2 AU) 3.7 (21.3–8.6) 22.4 (14.8–29.9) 49.9 (42.0–57.9) 31.6 (25.5–37.6)
Expt.3 (4 AU) 6.6 (1.2–12.0) 5.4 (0.1–10.6) 51.6 (42.6–60.7) 36.2 (28.0–44.4)
Mean of all Expts. 4.4 (0.3–8.6) 13.5 (6.1–20.9) 50.4 (44.9–55.9) 33.7 (29.8–37.5)
The assay was validated by repeated assessment of anti-FVO AMA1 antibody depletion by FVO, HB3, 3D7 and CAMP AMA1 competitor/soluble antigens, on FVO AMA1-
coated plates. Values are the estimated minimum residual binding and reported as minimum value (95% CI) for each of the competitor/soluble antigens. Assays were
performed on three different days with three different antibody dilutions (1 AU, 2 AU, 4 AU). 1 AU is equivalent to the antibody titre.
doi:10.1371/journal.pone.0008110.t001
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were recognized/depleted by CAMP AMA1 irrespective of the
coating antigen used (Table 2).
To further assess the nature of antibodies raised in a mixed
allele immunisation, protein A-purified antibody pools containing
anti-FVO/HB3, anti-FVO/3D7 and anti-HB3/3D7, as well as a
pool of antibodies against all three PfAMA1 alleles (anti-FVO/
HB3/3D7) were made from antibodies raised in the single allele-
immunised rabbits. These antibody pools were compared to
antibodies from single and mixed allele immunisations in
competition ELISA with FVO, HB3 or 3D7 AMA1 as coating
antigens. Depending on the coating antigen/IgG pool combina-
tion, there were small changes in depletion by the four native
PfAMA1 alleles compared to the IgGs from single allele
immunisations, with mixed significance (data not shown). The
antibody pools with anti-HB3 IgGs were predictably less
recognized by CAMP AMA1. Recognition/depletion patterns of
the pool of three (anti-FVO/HB3/3D7) were intermediate
between the observed patterns for antibodies from single and
mixed allele immunisations (Figure 1). Generally, there was the
tendency for greater depletion (lower residual binding) of anti-
Combi antibodies by all competitor antigens compared to the
Figure 1. Competition ELISA with protein A-purified antibodies and antibody pools made from single allele immunisations. A) Assay
on 3D7 AMA1-coated plates with anti-3D7 AMA1, anti-Combi (mixed allele immunisation) and anti-FVO/HB3/3D7 antibody pool. B) Assay on FVO
AMA1-coated plates with anti- FVO AMA1, anti-Combi and anti-FVO/HB3/3D7 antibody pool. C) Assay on HB3 AMA1-coated plates with anti- HB3
AMA1, anti-Combi and anti-FVO/HB3/3D7 antibody pool. IgG pools were made from antibodies raised in single allele immunisations with FVO, HB3
and 3D7 AMA1. All assays were performed with FVO, HB3, 3D7 and CAMP AMA1 proteins as competitor antigens. All IgGs were used at 2 times the
pre-determined antibody titre. Plots are representative of at least 2 assay repeats using IgGs from one rabbit per group since the depletion patterns
were similar for both rabbits in each immunisation group.
doi:10.1371/journal.pone.0008110.g001
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(Table 2). This suggests that although IgG pooling would result in
a decreased proportion of strain-specific antibodies, immunisation
with the mixed antigens yields even lower levels of antibodies to
epitopes that are specific to the component vaccine antigens.
In order to assess the functional capacity of these antibodies in
relation to the observations made by competition ELISA, growth
inhibition assays were performed with the FCR3 (one pro-
sequence amino acid difference from FVO AMA1), HB3, NF54
(with identical AMA1 to clone 3D7) and CAMP strains of P.
falciparum. In assays with NF54, HB3 and FCR3 parasite strains,
growth inhibition levels decreased more rapidly with decreasing
concentration of antibodies against heterologous PfAMA1 alleles
(Figure 2). Thus the extent of in vitro growth inhibition of any
parasite strain was dependent on the antibody source (homologous
versus heterologous), and generally for heterologous parasites, also
on the number of amino acid variants between the vaccine and
parasite AMA1 alleles (see Table 3). For example, the growth of
NF54 parasites was best inhibited by anti-3D7 AMA1 antibodies
and least by anti-FVO AMA1 antibodies over the 4 dilutions
tested, with anti-HB3 AMA1 antibodies yielding intermediate
inhibition (Figure 2). Most importantly, however, anti-Combi
antibodies resulted in growth inhibitions that were comparable
with that of antibodies from single allele immunisations on the
respective homologous parasite strains in all cases. Furthermore,
the anti-Combi antibodies yielded the best growth inhibition of
CAMP parasites compared to antibodies from the 3 single allele
immunisations, even though CAMP AMA1 was not included in
the mixed allele vaccine. The relatively similar ELISA titres of
mono-specific antibodies (950,000 for anti-FVO, 1,150,000 for
anti-HB3 and 1,280,000 for anti-3D7 AMA1) on the respective
homologous PfAMA1 alleles compared to anti-Combi antibodies
(1,230,000 on FVO, 1,140,000 on HB3 and 1,120,000 on 3D7
AMA1) as measured in protein G-purified fractions eliminates the
possibility of this observation being due to higher titres of anti-
Combi antibodies. The observed GIA activity cannot also be
attributed to a better quality of the anti-Combi antibodies since
these were shown to have antigen-binding capacities in the same
order as mono-specific antibodies when titres were normalized
(Table 4). The current observation may therefore be mainly
attributed to the induction of a more cross-reactive antibody
profile and represents a broadened inhibitory capacity of anti-
Combi antibodies compared to antibodies induced in single allele
immunisations.
GIAs with the antibody pools were also performed to assess the
trends in growth inhibition with respect to the varying antibody
specificities. Results showed that differences in growth inhibition
between the pools were dependent on the parasite strain/antibody
pool combination. The anti-FVO/3D7 antibody pool, for
example, inhibited the growth of CAMP parasites better
(Figure 2) than the other double pools (anti-FVO/HB3, anti-
HB3/3D7), even though these pools had similar antibody titres as
measured by ELISA (data not shown). This is likely due to the fact
that HB3 AMA1, being the most distant allele from CAMP AMA1
in terms of amino acid residues, shares fewer functional epitopes
with CAMP AMA1 such that the pools with anti-HB3 AMA1
antibodies cross-reacted least with CAMP AMA1, resulting in
relatively lower parasite growth inhibitions.
Inhibition of all strains by anti-Combi antibodies was higher
compared with the anti-FVO/HB3/3D7 IgG pool, confirming the
induction of higher levels of antibodies to common epitopes by
multi-allele immunisation. Antibodies to common allele epitopes
are predominantly induced since strain-specific epitopes on each of
the vaccine alleles have been diluted out in the vaccine antigen
mixture, and this translates to a broadened scope of PfAMA1
recognition. The functional assay therefore confirms observations
made by competition ELISA, and shows that mixed allele
immunisation predominantly yields antibodies to common allele
epitopes and low levels of antibodies to strain-specific epitopes.
High levels of antibodies to the common vaccine allele epitopes are
invariably required for broad strain inhibition.
Most Cross-Reactive Antibody Epitopes Are Shared by All
Alleles
To assess the relative contributions of strain-specific and cross-
reactive antibodies to overall antigen recognition and parasite
inhibition, strain-specific and cross-reactive antibody fractions
were affinity-purified from total IgGs of rabbits immunised with
Table 2. Residual IgG binding estimates for antibodies raised in single and multi-allele immunisations.
Coating antigen IgG Sample Competitor antigen (PfAMA1)
FVO HB3 3D7 CAMP
anti-FVO 3.7 (21.3–7.2) 22.4 (14.8–29.9) 49.9 (42.0–57.9) 31.6 (25.9–37.2)
FVO AMA1 anti-Combi 3.0 (21.3–7.2) 2.9 (0.1–5.8) 8.0 (3.1–12.9) 16.8 (12.6–20.9)
IgG pool
1 1.9 (27.1–10.9) 23.2* (215.9–9.4) 18.6 (12.5–24.7) 25.5 (14.1–36.8)
FVO HB3 3D7 CAMP
anti-3D7 40.2 (36.8–43.6) 29.9 (19.6–40.2) 3.3 (20.8–7.4) 40.0 (36.0–43.8)
3D7 AMA1 anti-Combi 17.8 (13.4–22.2) 5.7 (2.4–9.0) 1.9 (21.5–5.4) 25.7 (19.2–32.2)
IgG pool
1 29.9 (18.8–40.9) 2150* (2546–246) 23.0* (211.1–5.0) 34.6 (28.9–40.3)
FVO HB3 3D7 CAMP
anti-HB3 52.7 (46.2–59.1) 2.3 (26.0–10.5) 257.7* (2299–184) 55.0 (43.0–67.0)
HB3 AMA1 anti-Combi 15.1 (7.6–22.5) 22.2* (211.7–7.4) 7.5 (1.5–13.5) 18.8 (8.2–29.5)
IgG pool
1 21.2 (12.6–29.8) 2.1 (22.3–6.5) 3.3 (216.8–23.4) 32.9 (22.1–43.7)
Residual binding values are the predicted minimum values based on the measured values for each competitor antigen, and were generated with a four-parameter
logistic fit with least squares approximation. Values are estimated with the R statistical package and reported as % residual binding or minimum value (95%CI).
1A pool of IgGs from the single allele immunisations with FVO, HB3 and 3D7 AMA1.
*Negative estimate of residual binding (minimum values have not reached a plateau yet). Minimum values cannot be accurately estimated.
doi:10.1371/journal.pone.0008110.t002
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strain-specific IgG fractions for each of the two PfAMA1 alleles
were prepared with respect to the other allele (procedure presented
schematically in Figure S1). Up to 90% of recovered IgGs from
anti-3D7 AMA1 antibodies were cross-reactive with FVO AMA1,
while over 95% of recovered IgGs from anti-FVO AMA1
Table 3. Number of amino acid variants between vaccine and
Pf parasite AMA1 alleles.
Vaccine
antigen Parasite strain
NF54 HB3 FCR3 CAMP
3D7 *6 (2,3,1) 29 (15,8,6) 30 (19,8,3) 26 (14,9,3)
HB3 30 (16,8,6) *5 (1,3,1) 24 (13,7,4) 31 (17,8,6)
FVO 30 (19,8,3) 23 (12,7,4) *6 (2,3,1) 20 (11,6,3)
Values represent only the differences in domains I, II and III of PfAMA1
ectodomain. Differences per domain have been presented in brackets as
(domain I, domain II, domain III).
*The 6 variant amino acids between ‘‘homologous’’ AMA1 alleles (5 for HB3) are
due to amino acid substitutions introduced to prevent protein glycosylation
and cleavage. Substitutions occur at positions 162 and 288 in domain I
(position 288 only for HB3), positions 373, 422 and 423 in domain II, and
position 499 in domain III.
doi:10.1371/journal.pone.0008110.t003
Table 4. Measured avidity Indices for mono-specific and anti-
Combi antibodies against vaccine PfAMA1 alleles.
Avidity Index by capture antigen
Rb ID (Immunising Ag) FVO HB3 3D7
1455 (FVO) 1.23 0.91 1.01
1456 (HB3) 0.89 1.10 0.81
1459 (3D7) 1.15 1.03 1.38
1461 (Combi) 1.04 1.06 1.31
Avidity index of AMA1-specific antibodies was estimated as the concentration
of NaSCN required to dissociate 50% of AMA1-bound antibodies. The avidity
indices of mono-specific antibodies were determined against both the
immunising (‘‘homologous’’) allele and the other two ‘‘heterologous’’ alleles.
That for anti-Combi antibodies was determined against all vaccine component
alleles.
doi:10.1371/journal.pone.0008110.t004
Figure 2. Growth inhibition levels exhibited by protein A-purified IgGs from single/mixed PfAMA1 immunisations and IgG pools. All
IgG fractions were tested in a single growth cycle assay with FCR3, HB3, NF54 and CAMP strains of P. falciparum. For all strains, assays were performed
with 0.360.1% parasitaemia and a final haematocrit of 2%. IgG samples were tested at 4 dilutions (3-fold titration from 6 mg/ml). IgG pools were
made from antibodies raised in single allele immunisations with FVO, HB3 and 3D7 AMA1. The data presented is representative of at least two assay
repeats using IgGs from one of the two rabbits per group.
doi:10.1371/journal.pone.0008110.g002
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fractions were compared with the respective un-fractionated
affinity-purified anti-3D7 or anti-FVO IgGs by competition
ELISA. The strain-specific fraction of anti-3D7 AMA1 IgGs had
very little reactivity with HB3 and CAMP AMA1 alleles
(Figure 3A). There was however, an improved recognition and
depletion of IgGs in the cross-reactive fraction by all the
heterologous PfAMA1 alleles used (FVO, HB3, CAMP). Similar
observations were made with anti-FVO AMA1 strain-specific and
cross-reactive IgG fractions, except that the strain-specific fraction
of anti-FVO AMA1 IgG was still highly reactive with HB3 AMA1,
and to a lesser extent with CAMP AMA1 (Figure 3B). Based on
these observations, it is likely that FVO AMA1 may induce the
production of antibodies that are more cross-reactive in compar-
ison with 3D7 AMA1.
The affinity-purified antibody fractions were also tested for
functional capacity by in vitro growth inhibition assays on FCR3
(FVO), CAMP and NF54 (3D7) parasite strains (Figure 4). The
cross-reactive fractions alone had the same functional capacity on
homologous parasites as the respective total affinity-purified IgGs
when both were tested at the same concentrations. The anti-3D7
cross-reactive fraction showed slightly less inhibition on FCR3
heterologous parasites over the four antibody concentrations tested
as compared to the anti-FVO cross-reactive fraction, and the
reverse was true for the inhibition of NF54 parasites. Furthermore,
both cross-reactive fractions yielded slightly lower inhibition of
CAMP parasites compared to the inhibitions observed for same
fractions on their respective homologous parasites. By contrast, the
strain-specific fractions showed slightly less inhibition of red cell
invasion by homologous parasites compared to the cross-reactive
and total fractions. Both strain-specific fractions had negligible
inhibitory effect on heterologous parasites, including the CAMP
heterologous strains. These observations confirm the need to
induce cross-reactive antibodies in overcoming allelic diversity to
PfAMA1, but also show that the cross-reactive antibody fraction
from a single PfAMA1 allele immunisation may not be as efficient
for achieving significant parasite inhibition.
Discussion
Allelic polymorphism in AMA1 is due to single amino acid
substitutions and has been linked with host immune pressure on
the parasite [15,25]. Although this makes AMA1 a possible target
for natural as well as vaccine induced responses, polymorphism
presents the practical challenge of developing a broadly effective
vaccine since immunisation with one AMA1 haplotype appears
Figure 3. Competition ELISA with PfAMA1-specific IgG fractions. Anti-3D7 AMA1 IgGs were affinity-purified from total (Protein A) IgG of one
of the 3D7 AMA1-immunised rabbits. A portion of this IgG fraction was afterwards fractionated into 3D7 AMA1 strain-specific IgG (flow through) and
3D7/FVO cross-reactive IgG (eluate) by passage over an FVO AMA1 affinity matrix. Similar specific fractions were made from total IgGs from one of the
FVO AMA1-immunised rabbits, first over an FVO AMA1 matrix, and then over a 3D7 AMA1 matrix. All IgG fractions were used for competition assays
at 2 times the pre-determined antibody titre. AMA1 antigens from the 3D7, HB3, FVO and CAMP parasite strains were used as competitor antigens in
all assays. Assays were done using plates coated with 3D7 AMA1 (A) and FVO AMA1 (B), and plots are representative of data from at least 2 repeat
assays.
doi:10.1371/journal.pone.0008110.g003
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haplotypes [12]. Preliminary analysis of about 745 PfAMA1
amino acid sequences pulled from PubMed through GeneBank
shows 236 unique AMA1 haplotypes, with an estimated 189
occurring in domain I alone (unpublished data). An effective
vaccine is expected to protect against this diversity of parasites
globally or at least within a particular endemic region. It is worth
noting that while about 10% of amino acid residues in the AMA1
ectodomain are polymorphic, most of these residues are
dimorphic, a few are tri- or tetramorphic, and a single position
in domain I (197) is heptamorphic [25,28]. Polymorphic residue
linkages present within the molecule also tend to limit the choice of
amino acids in certain polymorphic positions [18], providing some
level of polymorphic stability. Overcoming PfAMA1 polymor-
phism is therefore a key step in vaccine development, and
immunisation with a mixture of PfAMA1 alleles has been
proposed as one possible solution to this challenge [3,17,18,37].
The aim of the present study was to determine the relative
functional importance of cross-reactive and strain-specific anti-
body fractions elicited upon immunisation with a particular
PfAMA1 allele, and also to assess the feasibility of achieving broad
strain recognition by antibodies to a multi-allele PfAMA1 vaccine.
We validated a competition ELISA assay for assessing antibody
specificities providing a highly reproducible and robust method-
ology for dissecting specific antibody responses to immunisation
with a PfAMA1-based vaccine. The assay was independent of the
specific antibody source (serum or purified IgG) and the antibody
dilution factor when the working OD values fell within the linear
portion of the standard/calibration curve. The latter observation
may be explained by the fact that the antigen-antibody complex
reaction, being reversible, would always have very similar
percentage proportions of reaction components when it attains a
dynamic equilibrium state. It is also worthwhile noting that the
anti-PfAMA1 antibody depletion patterns observed for the various
competitor PfAMA1 alleles in competition assays were generally
predictive of the extent of growth inhibition of the different
parasite strains by the anti-PfAMA1 antibodies in vitro.
The major findings of this study are that i) immunisation with a
mixture of allelic PfAMA1 forms predominantly induces the
production of cross-reactive anti-PfAMA1 antibodies, and ii) the
cross-reactive fraction of antibodies to any PfAMA1 allele has the
same functional capacity (GIA) as the total anti-PfAMA1
antibodies (cross-reactive+strain-specific) at the same concentra-
tion, hence induction of antibodies to epitopes that are common to
a number of PfAMA1 alleles will not reduce the inhibitory
capacity against parasites expressing any of the vaccinating alleles.
The increased recognition and depletion of anti-Combi
antibodies by all competitor antigens, including the out-group
antigen CAMP, compared to that of mono-specific antibodies
implies a broadened antibody response (Figure 1). This is most
Figure 4. Representative data showing levels of parasite growth inhibition exhibited by affinity-purified AMA1-specific IgG
fractions. All fractions were tested for functional activity on FCR3, NF54 and CAMP strains of P. falciparum. For all strains, assays were done with
0.360.1% parasitaemia and a final haematocrit of 2%. IgG samples were tested at 4 dilutions (3-fold titration from 1 mg/ml). Anti-FVO and anti-3D7
are the respective total affinity-purified IgGs, anti-FVO CR and anti-3D7 CR designate the cross-reactive fractions, while anti-FVO spec and anti-3D7 spec
designate the respective strain-specific fractions.
doi:10.1371/journal.pone.0008110.g004
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that are common to the component alleles of the vaccine, and
similar observations have been made in earlier studies [17,27,37].
Since strain-specific epitopes on each vaccine allele are expected to
be present at relatively low quantities in the mixture, they will have
a decreased probability of presentation to the relevant immune
system effectors compared to common epitopes. Indeed, the levels
of antibodies to common epitopes in the mixed allele immunisa-
tion, as assessed by competition ELISA assays, were constantly
higher relative to the levels in antibody pools made from the three
single immunisations with the same antigens (Figure 1).
This was confirmed by the growth inhibition patterns observed
when all antibody fractions were tested against the FCR3, HB3,
NF54 and CAMP parasite strains (Figure 2).
Recognition and depletion of affinity-purified IgG fractions
from FVO and 3D7 AMA1 mono-specific immunisations provide
further evidence for the induction of antibodies against common
epitopes. Most ($80%) of the cross-reactive epitopes between
these two PfAMA1 alleles are shared with CAMP and HB3 AMA1
alleles (Figure 3). Additionally, for the anti-3D7 IgG fraction,
affinity depletion of anti-FVO cross-reactive antibodies removed
up to 80% of antibodies reactive to the HB3 and CAMP AMA1
alleles. These observations may possibly extend to the many other
PfAMA1 alleles not tested in this study. The patterns of
recognition and depletion of the affinity-purified, cross-reactive
fractions closely resemble those of antibodies induced by the mixed
allele immunisation in ELISA.
Observations from competition ELISA were confirmed by
functional parasite growth inhibition assays with the FCR3, NF54,
HB3 and CAMP strains of P. falciparum. The extent of antigen
recognition by these antibody fractions was predictive of the
degree of functional parasite inhibition observed in vitro. Further-
more, assays with affinity-purified anti-PfAMA1 antibodies on
FCR3 and NF54 parasite strains showed that at the same
concentration, the cross-reactive fractions had the same growth
inhibitory effects as the total anti-PfAMA1 IgGs on homologous
parasites, while the strain-specific fractions had slightly lower
inhibitions over the IgG concentrations tested (Figure 4). Thus in
the absence of the strain-specific fraction of antibodies against any
PfAMA1 allele, the cross-reactive fraction alone is still highly
inhibitory against homologous parasites. The limited cross
inhibition of heterologous parasites by antibodies from single
allele immunisations may therefore be attributed to the propor-
tions of cross-reactive and strain-specific antibodies; the cross-
reactive antibody fraction may not be enough to effectively inhibit
heterologous parasite invasion of RBCs to the same extent as
homologous strain inhibition, which would involve both cross-
reactive and strain-specific antibody activity.
Cross-reactive antibody fractions of both anti-FVO and anti-
3D7 AMA1 IgGs, initially derived from mono-specific sera,
inhibited the respective heterologous strains less effectively in vitro
(Figure 4). Since the same concentration of both antibody fractions
resulted in greater growth inhibition of the respective homologous
parasites, the current observation may be a potential consequence
of the affinity purification process, or logically due to avidity
differences in binding to homologous and heterologous parasite
PfAMA1 alleles. This latter observation, if confirmed, would imply
that the cross-reactive fraction of antibodies generated by single
allele immunisation may not be as equally good as cross-reactive
antibodies induced by multi-allele immunisation in terms of
functional capacity against heterologous parasites.
The measured avidity indices for anti-Combi and mono-specific
antibodies on the immunising antigen(s) as well as for mono-
specific antibodies on ‘‘heterologous’’ PfAMA1 alleles were
comparable (Table 4). Due to antibody titre normalization
however, the quantity of each mono-specific serum that was used
for the avidity determination on heterologous alleles was up to 2-
fold higher than the quantity of mono-specific and anti-Combi
antibodies used on the respective homologous alleles. Thus cross-
reactive antibodies, irrespective of the source, bound the allelic
PfAMA1antigens to very similar degrees, and the only factor that
influences the extent of in vitro parasite inhibition was the absolute
levels of these functional antibodies. These observations, taken
together with the fact that the functional activity of antibodies is
generally linked with their antigen binding strength [38,39],
support the conclusion that anti-Combi antibodies are most likely
high-avidity in nature. Additionally, most low-avidity antibodies
are likely to be lost during affinity purification of PfAMA1-specific
antibodies. Depletion patterns for the affinity-purified cross-
reactive fractions from both anti-3D7 and anti-FVO AMA1
antibodies (Figure 3) were however, similar to those of anti-Combi
antibodies (Figure 1) which were Protein A-purified and should
therefore include any low-avidity AMA1-specific antibodies. The
absence of such low-avidity, cross-reactive antibodies after affinity
purification would be expected to result in antibody depletion
patterns that are rather similar to those of mono-specific
antibodies (Figure 1).
Considering the data presented, it may be hypothesized that
apart from antibody specificity, an optimal concentration of
antibodies is also necessary in order to achieve a good degree of
parasite inhibition. These findings are important for two main
reasons, that i) there is no loss in in vitro inhibitory capacity by
mainly inducing antibodies to common epitopes, and ii) the
antibodies thus induced will also cross-react with epitopes on other
PfAMA1 alleles that are similar to those on the vaccine’s
component alleles to which they were raised. High titres of
antibodies to such common epitopes imply broadened recognition
and inhibition of a wide range of parasite strains. Taken together,
these results provide evidence for the induction of high levels of
inhibitory antibodies to common epitopes by immunisation with a
mixture of PfAMA1 alleles. An added advantage of this strategy
over a typical multi-antigen or multistage vaccine is the possible
limitation on the number of different antigens (with very different
epitopes) that can be practically included in a multistage vaccine
formulation without compromising effectiveness. Such a multi-
stage vaccine may induce low antibody titres to each of a wide
variety of antigens/epitopes, some of which may not be anti-
parasitic enough, such that the overall response will be affected by
the reduced effective antibody concentration [27,40,41]. A multi-
allele strategy with a promising antigen like PfAMA1, by
comparison, will focus the humoral response on relevant epitopes
that are common to all constituent alleles. In theory, increasing the
number of constituent alleles will reduce the number of common/
overlapping epitopes and these repeated epitopes will form the
bulk of all epitopes present in the mixture. This would be expected
to translate to relatively higher antibody titres against these
common epitopes, with the result being broad antibody specificity.
Duan and others [42] have recently proposed such an approach,
with a recommended minimum of six PfAMA1 alleles as
components of a universal vaccine. The number of alleles that
can be practically included in such a vaccine may however be
limited by high costs (of producing six different proteins) and/or
practical developmental difficulties (of expressing fusion proteins
with six component antigens), especially if AMA1 is to be
combined with other highly immunogenic antigen(s) in a multi-
antigen vaccine. On this basis, the diversity covering approach
[18], comprising three synthetic and highly divergent PfAMA1-
based proteins, appears to be a more practical approach to
AMA1 Multiallele Immunisation
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the three DiCo antigens are expected to have fewer common/
overlapping antibody epitopes. These would nevertheless repre-
sent the greater proportion of antibody epitopes in the DiCo
mixture, and would induce high antibody titres upon immunisa-
tion. It is therefore practically possible and more cost-effective to
induce a significantly broad humoral response to P. falciparum
strains using the DiCo proteins, at least as components of a multi-
antigen vaccine.
In summary, the present study has shown that broad functional
specificity of anti-PfAMA1 antibodies to diverse P. falciparum strains
can be achieved by multi-allele immunisation. The humoral
response is most likely focused on epitopes that are common to
the constituent alleles, which would form the bulk of all epitopes
present, and leads to induction of antibodies to these common
epitopes. The results also show that majority of B cell epitopes are
shared by the PfAMA1 alleles used in this study, and possibly by
many other PfAMA1 alleles. Thus antibodies induced against a
multi-allele vaccine are also highly likely to be effective against
parasites expressing diverse PfAMA1 alleles. Of central importance
to this immunisation strategy is the demonstration of good levels of
homologous parasite inhibition by cross-reactive anti-PfAMA1
antibodies, compared to the total antibody fraction at the same
concentration in vitro. This is necessary to ensure that in aiming to
broaden the antibody response, functionality against parasites
expressing the vaccine PfAMA1 alleles is not compromised.
Supporting Information
Figure S1 Schematic presentation of strain-specific and cross-
reactive anti-AMA1 antibody purification. Cross-reactive and
strain-specific IgG fractions of anti-3D7 AMA1 IgGs (A) and anti-
FVO AMA1 IgGs (B) were isolated from sera of the respective
mono-specific AMA1-immunised rabbits. Serum IgGs were first
purified over protein A sepharose columns before affinity
fractionation.
Found at: doi:10.1371/journal.pone.0008110.s001 (0.13 MB TIF)
Figure S2 Competition ELISA using different dilutions of anti-
FVO AMA1 antibodies with FVO AMA1-coated plates. The
assay involves co-incubation of a soluble/competitor antigen with
antibodies in an antigen-coated plate such that there is
competition between the coated and soluble/competitor antigens
for binding to test antibodies. Protein A-purified anti-FVO AMA1
antibodies were used at dilutions equivalent to 0.2, 0.5, 1, 2, 4 and
8 times the antibody titre (1 AU, the IgG dilution that yields an
OD405 of 1.0). Each dilution of antibody was added to FVO
AMA1-coated plates with soluble/competitor AMA1 antigens
from the 3D7, HB3, FVO and CAMP parasite strains, each
titrated from 30–0.005 mg/ml in duplicate wells. Antibodies that
are not depleted by the soluble/competitor antigens bind to the
coated antigen (residual binding), and the resulting optical
densities (OD) were expressed as percentages of ODs from reagent
wells with antibody but no competitor antigens. Competitor
antigen concentrations (log transformed) were then plotted against
the percent residual binding for all competitor antigens. Depletion
patterns for competitor/soluble FVO or sFVO (A), sHB3 (B),
s3D7 (C) and sCAMP (D) AMA1 antigens at the different antibody
dilutions are shown.
Found at: doi:10.1371/journal.pone.0008110.s002 (0.09 MB TIF)
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